857
·
03-03
$TSLA, $NVO, $NVDA / $QQQ Highlight Critical Monthly BX Signals
March is shaping up as a pivotal month for these major names. Monthly BX readings show $TSLA at a key bounce point, $NVO experiencing a decisive rotation, and $NVDA / $QQQ flashing cautionary bearish signals. Data-driven moves are crucial—protect capital, not feelings. 1. $Tesla Motors(TSLA)$ If $TSLA is going to bounce, this is the spot. Huge month coming up: without strong follow-through, Monthly BX can close dark red and flip the script. For now, all our criteria are still met, so I remain bullish on $TSLA. 2. $Novo-Nordisk A/S(NVO)$ I just took a 27% loss on $NVO … and I’d still take that trade again. BX was bullish, criteria was met, then the stock nuked and Monthly BX flipped red. I cut it and rotate
21.56K
·
03-03
Mag 7 at Historical Low! Who is Gifting an "Entry Point"?
As of early March 2026, Mag 7 have faced a collective pullback, fueled by escalating geopolitical tensions in the Middle East and growing skepticism over the AI capex. However, this volatility has created a historic technical setup: $NVIDIA(NVDA)$ and $Microsoft(MSFT)$ have once again plunged into their most "undervalued" territory in five years.For veteran investors, this isn't just a correction, it’s the market "handing out checks" again. Let’s look at the valuation landscape through the lens of the March 2nd closing data:1. $NVIDIA(NVDA)$ is trading at roughly 21.5x Forward P/E, another cheapest level over the past five years.Nvidia’s FY2026 Q4 results were no
TOPicycrystal: As of March 3, 2026, analysts maintain a strong bullish outlook on both Nvidia and Microsoft, despite recent volatility. Microsoft, currently trading at $394.17, is viewed by many as a bargain at the $400 level with significant upside potential. Meanwhile, Nvidia remains a "Strong Buy" ahead of its upcoming GTC conference, though the broader market is beginning to shift some focus toward other sectors like Energy and Industrials as the "Magnificent Seven" trade diversifies. Is Microsoft a Buy at $400? Wall Street analysts overwhelmingly consider Microsoft a "Strong Buy" at its current price. Nvidia's GTC conference (March 2026) is widely expected to be a major catalyst. Conference Outlook: Analysts from Bank of America and Wells Fargo view recent price dips as a favorable buying opportunity ahead of the event, anticipating positive updates on the Rubin GPU platform and networking growth.
1.01K
·
03-03
$SPX Triangle Complete Target 6,720–6,500 Watch 6,915 Close
The triangle I've been tracking on $S&P 500(.SPX)$ is nearing completion, if not already complete. A-B-C-D-E. Textbook. Right into the Daily FVG resistance at 6,883–6,915. This is where it terminates. What follows is a sharp C-Wave decline to SPX 6,720–6,500. ⚠️: Daily close above 6,915 threatens crossing the triangle invalidation at 6,953. The setup is here. The move is next. Bookmark this. PS: New weekly update — setting the stage for a pivotal week. $SPX holds a bearish triangle setup and could see a sharp resolution lower as soon as this week. 6,720 is the high probability target with downside scope to 6,500. For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG,
TOPGood analysis , though the NDX seemed to have already completed the bearish pattern. Let’s wait and see. Thx
848
·
03-03
Option layout strategy under gold's surge and shock
Recently due toThe situation in the Middle East escalates(The United States and Israel launch military operations against Iran, etc.), market risk aversion has heated up, gold, as a traditional safe-haven asset, is favored by funds, and the price onceImpact high。 Multiple reports show spot and futures gold prices supported by safe-haven buyingOnce rose sharply。 But it also appears at high levelsVolatility adjustment: Due to factors such as the strengthening of the US dollar and changes in risk appetite, the price of gold has experienced a technical pullback/retracement or consolidation, suggesting that the market's expectations for the persistence of the conflict are inconsistent. In addition, in different markets around the world, the short-term amplitude of gold prices has increased sign
401
·
03-03
PLTR rallies above 145 as bulls push toward $150 zone
$Palantir Technologies Inc.(PLTR)$ Palantir Technologies Inc.(PLTR) Rallied +5.82%: Momentum Surges Above $145 as Bulls Target $150 Zone Latest Close Data: As of March 2, 2026, PLTR closed at $145.17, a strong gain of +5.82% from the previous close. The stock remains approximately 30% below its 52-week high of $207.52. Core Market Drivers: The price action reflects ongoing market optimism for AI and data analytics platforms, with Palantir being a key beneficiary. A significant net capital inflow of ~$164 million for the day suggests strong buying interest, potentially driven by broader tech sector strength and anticipation of continued government and commercial contract momentum. Technical Analysis: The rally was supported by robust volume (1.41x
1.22K
·
03-02
$ProShares Ultra Silver(AGQ)$
420
·
03-02
$Pacific Biosciences of California(PACB)$ resilience on current weak market. Long term bullish.
366
·
03-02
$GLD US$(O87.SI)$ Good to buy kore ?
338
·
03-02
$NVIDIA(NVDA)$ Call me Ah Puh Neh~ 😉
357
·
03-02
$Apple(AAPL)$ Rental incomes adds to income tax. If you’re in a high bracket, it will eat up most of the delta. Would only do it if the delta is >> income tax, or if I’m squeezing income sources to raise my mortgage limit or cash flow whatsoever.
TOPTaxes chew up gains! Only worth it for massive profits, mate.[吃瓜]
497
·
03-03
$NVIDIA(NVDA)$ still a global leader in AI. You must own this great company stock in your portfolio as well
366
·
03-03
$NIO 20260618 7.0 CALL$ Will Nio shares rise after earnings? 🤔
295
·
03-03
$TSLA 20260515 450.0 CALL$ fortunately. But also hope tesla doesnt drop much
627
·
03-03
$Tesla Motors(TSLA)$ long term holdings
2.01K
·
03-03
$NVIDIA(NVDA)$
627
·
03-03
$AEM SGD(AWX.SI)$ Managed to catch AI wave! Will keep her to see how high can she get.... $4?
612
·
03-03
$AI rebounds from 52 week low as short squeeze targets $8.68 resistance
$C3.ai, Inc.(AI)$ C3.ai, Inc. (AI) Jumps +8.81%: Bouncing from 52-Week Low as Shorts Squeeze, Eyeing $8.68 Resistance Latest Close Data Closed at $8.65 (Mar 2, 2026), up +8.81% (+$0.70). The stock rebounded from its 52-week low of $7.72, now trading -71.4% below its 52-week high of $30.24. Core Market Drivers A significant intraday reversal from the 52-week low suggests a potential short squeeze, supported by net positive capital inflow of ~$1.89M. The broader market's focus on AI infrastructure spending may be providing a sentiment lift for the sector. Technical Analysis Volume was strong at 12.26M shares (turnover 8.71%). The RSI (6) rebounded from oversold territory at 18.41 to 34.09, indicating renewed buying momentum. However, MACD remains in n
981
·
02-26
Hunting for Stocks Trading Far Below Analysts’ Average Target Prices
Seeking out stocks trading well below analysts’ average target prices is often an effective way to uncover potential new additions to an investment portfolio. Investors should certainly not rush into buying based solely on this metric and need to conduct further in-depth research. Yet using it as a starting point for screening can help you quickly zero in on targets poised for substantial gains in the future. Wall Street is currently quite bullish on two stocks: $IONQ Inc.(IONQ)$ and $SoundHound AI Inc(SOUN)$ . Analysts covering IonQ have set an average target price of $74.89 for the stock, which is currently trading at around $33.30. This translates to a staggering potential upside of 125% based on the t
839
·
02-26
Regeneron Pharmaceuticals: A Biotech Leader Poised for Long-Term Outperformance Despite Sector Under
While the healthcare sector has underperformed the broader market in recent years, there are still plenty of stocks with long-term investment value within the industry. $Regeneron Pharmaceuticals(REGN)$ , a leading enterprise in the biotech space, is well-positioned to outperform the market over the next decade, backed by its core product strengths and a robust research and development (R&D) pipeline. Core Growth Driver Maintains Strong Momentum Dupixent currently stands as the company’s most critical product driving revenue growth. Co-developed with Sanofi, this drug has been approved for indications such as atopic dermatitis and holds a leading position in its therapeutic areas. In 2024, Dupixent achieved a major milestone with the approval